Dataset Information

Identification of a novel signature based on immune microenvironment to predict prognosis，immunotherapeutic efficacy and immunogenicity in lung adenocarcinoma

ABSTRACT: Abstract: Immunotherapy has emerged as a crucial treatment approach for lung adenocarcinoma (LUAD), yet a notable percentage of patients do not exhibit the anticipated prognosis and therapeutic response. In this study, we embarked on a comprehensive analysis of immune infiltration-related genes in LUAD by integrating transcriptome sequencing data and TCGA dataset. And an immune risk prognosis model was developed, which accurately forecasts the prognosis and predicts the immunotherapy efficacy in LUAD. Patients with LUAD were categorized into high-risk and low-risk groups based on the model's risk value. The high-risk group exhibited a poorer prognosis, higher tumor mutation burden (TMB), greater genomic heterogeneity and lower immune scores. In contrast, the low-risk group manifested characteristics conducive to immunotherapy, including a more favorable prognosis, heightened sensitivity to immunotherapy and reduced likelihood of immune escape. The robustness of the model's predictive capability was corroborated using the GEO dataset, Nomogram and an independent immunotherapy cohort. Furthermore, the model risk value was found to be significantly associated with the prognosis of LUAD patients, genomic heterogeneity, immune cell infiltration, immune regulation and immunotherapy outcomes. Additionally, we characterized the significance of the model's feature factors using single-cell clustering and pseudo-temporal analysis, revealing that the model's feature genes are predominantly located in tumor-infiltrating T cells, particularly in the exhausted and effector subtypes. TNFRSF11A emerged as a key gene in the model, promoting LUAD cell proliferation, migration, and apoptosis, and involvement in LUAD M6A methylation and PD-L1-mediated immune escape. TNFRSF11A was mainly expressed in T cell clusters and represented a potential immune system regulatory factor associated with T cell exhaustion, fostering malignant progression in LUAD cells. Our study offers new mechanistic insights and therapeutic targets for the biological behaviors and immune suppression in LUAD.

ORGANISM(S): Homo sapiens

PROVIDER: GSE270711 | GEO | 2024/09/30

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Purpose: Mutations in STK11 (LKB1) occur in 17% of lung adenocarcinoma (LUAD) and drive a suppressive (cold) tumor immune microenvironment (TME) and resistance to immunotherapy. The mechanisms underpin the establishment and maintenance of a cold TME in LKB1 mutant LUAD remain poorly understood and the identification of downstream effectors is critical to inform therapeutic strategies to invigorate antitumor immunity. In this study, we investigated the association between inactivation of AMPK, one of the downstream substrates of LKB1, and immune evasion in human LUAD as well as the causal role of AMPK on TME in genetically engineered mouse model (GEMM) of LUAD. Experimental Design: We modeled AMPK inactivation in vivo using GEMM by deleting both AMPKα1 (Prkaa1) and AMPKα2 (Prkaa2) in KrasG12D-driven LUAD (KAA). Furthermore, we investigated the impact of AMPK inactivation on immune cell infiltration and global gene-expression programs of murine LUAD. Gene expression signature from AMPK-deficient murine LUAD was further compared to that of Lkb1 deficient murineLUAD as well as human LUAD with either LKB1 mutation or attenuated AMPK phosphorylation. Results: Inactivation of both AMPKα1 and AMPKα2 accelerates KrasG12D-driven LUAD. AMPK-deficient tumors are characterized with reduced infiltration of CD8+/CD4+ T cells and gene signatures associated with compromised immune microenvironment, which resembles LKB1-deficient murine and human LUAD (KL) as well as LKB1-wildtype LUAD with reduced AMPK phosphorylation. Attenuation of the MHC Class 1 component ß2 microglobulin (ß2M) was identified as a shared feature in KL and KAA murine LUAD as well as in human LUAD with either LKB1 mutations or reduced AMPK phosphorylation. Furthermore, reactivation of AMPK by expression of constitutive active form of AMPKα1 leads to restoration of ß2M level in LKB1 mutant LUAD cells. Conclusions: The results identify attenuation of the LKB1 substrate AMPK as an important mechanism for decreased MHC Class 1 expression and immune evasion in LKB1 mutant LUAD. Translational relevance: LKB1 loss-of-function mutations rank as the third most common genetic alterations found in lung adenocarcinoma and associated with immune evasion. In the current study, on the basis of GEMM of LUAD we established the causal relationship between inactivation of the LKB1 substrate AMPK and immune evasion. Furthermore we find that the status of AMPK phosphorylation is more sensitive than LKB1 mutation in predicting impaired tumor immune microenvironment and likely also for the resistance to immunotherapy. The results also suggest that restoration of AMPK activity could increase the number of patients benefiting from immunotherapy.

Project description:Glutamine (Gln) metabolism has been reported to play an essential role in cancer. However, a comprehensive analysis of its role in lung adenocarcinoma is still unavailable. This study established a novel system of quantification of Gln metabolism to predict the prognosis and immunotherapy efficacy in lung cancer. Further, the Gln metabolism in tumor microenvironment (TME) was characterized and the Gln metabolism-related genes were identified for targeted therapy. We comprehensively evaluated the patterns of Gln metabolism in 513 patients diagnosed with lung adenocarcinoma (LUAD) based on 73 Gln metabolism-related genes. Based on differentially expressed genes (DEGs), a risk model was constructed using Cox regression and Lasso regression analysis. The prognostic efficacy of the model was validated using an individual LUAD cohort form Shandong Provincial Hospital, an integrated LUAD cohort from GEO and pan-cancer cohorts from TCGA databases. Five independent immunotherapy cohorts were used to validate the model performance in predicting immunotherapy efficacy. Next, a series of single-cell sequencing analyses were used to characterize Gln metabolism in TME. Finally, single-cell sequencing analysis, transcriptome sequencing, and a series of in vitro experiments were used to explore the role of EPHB2 in LUAD. Patients with LUAD were eventually divided into low- and high-risk groups. Patients in low-risk group were characterized by low levels of Gln metabolism, survival advantage, “hot” immune phenotype and benefit from immunotherapy. Compared with other cells, tumor cells in TME exhibited the most active Gln metabolism. Among immune cells, tumor-infiltrating T cells exhibited the most active levels of Gln metabolism, especially CD8 T cell exhaustion and Treg suppression. EPHB2, a key gene in the model, was shown to promote LUAD cell proliferation, invasion and migration, and regulated the Gln metabolic pathway. Finally, we found that EPHB2 was highly expressed in macrophages, especially M2 macrophages. It may be involved in the M2 polarization of macrophages and mediate the negative regulation of M2 macrophages in NK cells. This study revealed that the Gln metabolism-based model played a significant role in predicting prognosis and immunotherapy efficacy in lung cancer. We further characterized the Gln metabolism of TME and investigated the Gln metabolism-related gene EPHB2 to provide a theoretical framework for anti-tumor strategy targeting Gln metabolism.

Dataset Information

Identification of a novel signature based on immune microenvironment to predict prognosis，immunotherapeutic efficacy and immunogenicity in lung adenocarcinoma

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure